--:--:--LOCAL ·--:--UTC
    US EQUITIESLAST CLOSE
    AAPL$349.21-0.92%
    MSFT$498.30-1.97%
    GOOGL$272.66-3.46%
    AMZN$257.37-3.87%
    NVDA$145.98-3.30%
    META$596.22-3.27%
    TSLA$374.41-2.43%
    NFLX$58.46-2.27%
    BRK.B$572.04-0.45%
    AVGO$346.65-2.09%
    DIS$120.25-1.72%
    SBUX$104.47-4.25%
    MCD$272.35-0.61%
    NKE$34.33-5.45%
    COST$1093.83-0.25%
    WMT$126.04-1.04%
    HD$336.68-0.28%
    KO$96.09-2.04%
    PG$167.85-1.43%
    ORCL$110.57-2.92%
    CRM$183.31-3.72%
    ADBE$221.68-2.00%
    AMD$489.19-7.72%
    INTC$55.72+1.92%
    QCOM$162.01+1.38%
    CSCO$94.70-2.55%
    IBM$223.88-2.03%
    UBER$65.60-4.60%
    ABNB$172.79-4.12%
    SHOP$131.97-5.34%
    PYPL$56.37-2.63%
    COIN$108.87-1.48%
    PLTR$153.68-1.91%
    HOOD$68.65-0.75%
    JPM$320.22-1.20%
    V$402.25-3.12%
    MA$626.50-2.62%
    BAC$48.57-0.70%
    GS$847.53-2.94%
    LLY$1351.12-2.29%
    UNH$330.48-5.55%
    JNJ$267.14-2.04%
    PFE$27.54-1.85%
    XOM$158.93-1.03%
    BA$160.51-1.47%
    BABA$83.31-1.26%
    TSM$352.09-2.90%
    US EQUITIESLAST CLOSE
    AAPL$349.21-0.92%
    MSFT$498.30-1.97%
    GOOGL$272.66-3.46%
    AMZN$257.37-3.87%
    NVDA$145.98-3.30%
    META$596.22-3.27%
    TSLA$374.41-2.43%
    NFLX$58.46-2.27%
    BRK.B$572.04-0.45%
    AVGO$346.65-2.09%
    DIS$120.25-1.72%
    SBUX$104.47-4.25%
    MCD$272.35-0.61%
    NKE$34.33-5.45%
    COST$1093.83-0.25%
    WMT$126.04-1.04%
    HD$336.68-0.28%
    KO$96.09-2.04%
    PG$167.85-1.43%
    ORCL$110.57-2.92%
    CRM$183.31-3.72%
    ADBE$221.68-2.00%
    AMD$489.19-7.72%
    INTC$55.72+1.92%
    QCOM$162.01+1.38%
    CSCO$94.70-2.55%
    IBM$223.88-2.03%
    UBER$65.60-4.60%
    ABNB$172.79-4.12%
    SHOP$131.97-5.34%
    PYPL$56.37-2.63%
    COIN$108.87-1.48%
    PLTR$153.68-1.91%
    HOOD$68.65-0.75%
    JPM$320.22-1.20%
    V$402.25-3.12%
    MA$626.50-2.62%
    BAC$48.57-0.70%
    GS$847.53-2.94%
    LLY$1351.12-2.29%
    UNH$330.48-5.55%
    JNJ$267.14-2.04%
    PFE$27.54-1.85%
    XOM$158.93-1.03%
    BA$160.51-1.47%
    BABA$83.31-1.26%
    TSM$352.09-2.90%
    Plug stock market data into your AI agent — one command: Get your free API key →
    LoginGet API Key
    Company data coverage · NASDAQ

    ALNY — ALNYLAM PHARMACEUTICALS, INC.

    Data coverage, completeness and provenance for ALNYLAM PHARMACEUTICALS, INC. in the Stock Market API — Health Care · Biotechnology.

    NASDAQ USA NASDAQ 100
    Core-field completeness
    94.1%
    Statement periods
    FY2021–FY2025
    Filings archived
    0
    Price collection time
    2026-11-19 22:33 UTC

    Stored price coverage

    Source date: 2026-11-19T21:00:01. Source: yfinance. Collection time is shown separately and does not establish a trade date.

    Recent stored price bars, without investment interpretation
    DateCloseCurrencySourceAdjustment basis
    2026-11-19147.8200USDyfinanceSplit- and dividend-adjusted close
    2026-11-18149.4000USDyfinanceSplit- and dividend-adjusted close
    2026-11-17156.5000USDyfinanceSplit- and dividend-adjusted close
    2026-11-16159.7300USDyfinanceSplit- and dividend-adjusted close
    2026-11-13165.0400USDyfinanceSplit- and dividend-adjusted close

    GET /api/v1/companies/ALNY/prices · Price parameters and adjustment semantics

    No archived filings are currently stored for this listing.

    Dataset availability · Handle missing data

    Profile

    Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.

    Employees: 2,500 · Website: https://www.alnylam.com · Profile fields populated: 75%

    Data completeness by statement

    Share of stored fields populated in the anchor reporting period (FY2025), primary source sec_edgar. Full per-field breakdown: GET /api/v1/companies/ALNY/financials.

    Income statement10/10 fields (100.0%)
    Balance sheet12/14 fields (85.7%)
    Cash flow5/6 fields (83.3%)
    Per-share3/4 fields (75.0%)

    Financial statement coverage (USD)

    Stored values for the most recent fiscal-year periods, with per-period field counts and the primary source each period came from. Values are shown at reported scale without interpretation.

    PeriodPeriod end RevenueNet incomeTotal assetsTotal equity Fields populatedSource
    FY2025 (USD) 2025-12-31 30 sec_edgar
    FY2024 (USD) 2024-12-31 29 sec_edgar
    FY2023 (USD) 2023-12-31 29 sec_edgar
    FY2022 (USD) 2022-12-31 29 sec_edgar
    FY2021 (USD) 2021-12-31 29 sec_edgar

    Get ALNY data via the API

    The endpoints below describe available datasets for this listing. Missing fields remain unknown. Free API keys — no card required.

    Company profile

    Name, sector, industry, HQ, employees, market cap, source-tagged.

    GET /api/v1/companies/ALNY

    Financial statements

    Multi-year statements with per-field source tags and completeness.

    GET /api/v1/companies/ALNY/financials

    Computed ratios

    P/E, P/B, ROE, ROA, margins, EPS, debt/equity — formulas documented.

    GET /api/v1/companies/ALNY/metrics/summary

    News & announcements

    Dated press releases and announcements with source links.

    GET /api/v1/companies/ALNY/news

    Quick start

    Create a free key, then:

    curl -H "X-API-Key: KEY" https://stockmarketapi.ai/api/v1/companies/ALNY

    Query ALNY programmatically

    Free tier — instant API key. Built for AI agents.

    Frequently Asked Questions

    What data does the API provide for ALNY?
    Stored coverage for ALNY: price data available, financial statements available, 0 archived filings. REST endpoints are under /api/v1/companies/ALNY; inspect available source metadata for provenance.
    How complete is ALNY's financial data?
    The anchor reporting period (FY2025) has 94.1% of the 17 core statement fields populated. Primary source: sec_edgar.
    What reporting periods are covered for ALNY?
    5 fiscal-year periods are stored (FY2021–FY2025), with per-period field counts and source tags available via /api/v1/companies/ALNY/financials.
    Where does ALNY's data come from?
    Stored price source: yfinance. Primary source for the statement snapshot: sec_edgar. Inspect available period and field source tags at /api/v1/companies/ALNY/financials; missing tags do not establish provenance.